862 An integrated preclinical platform utilizing HLA-humanized mouse models for comprehensive evaluation of mRNA cancer vaccines
Year: 2026
Type: conference-abstract
Abstract: Background mRNA-based cancer vaccines are a promising immunotherapeutic modality that elicits potent, antigen-specific adaptive immune responses through antigen-presenting cell (APC) processing. However, wild-type mice with murine MHC fail to recapitulate human HLA-restricted T-cell responses, limiting translational predictivity. To address this, GemPharmatech has developed an integrated preclinical platform combining in vitro human immune cell immunogenicity screening with in vivo efficacy and safety assessment in a diverse panel of HLA-humanized mouse models.Methods In vitro, monocyte-derived dendritic cells were matured, loaded with mRNA antigens via electroporation or LNPs, and co-cultured with autologous T cells. Antigen-specific responses were measured by ELISpot and flow cytometry for early antigen screening, HLA affinity, and immunostimulatory potential. For in vivo evaluation, proprietary HLA-humanized mouse strains were generated on immunocompetent (C57BL/6, BALB/c, CB6F1) and immunodeficient NCG backgrounds. These models support assessment of vaccine immunogenicity, antitumor efficacy, and combination therapies.Results HLA-humanized immunocompetent mice, particularly CB6F1 strains, mounted robust combined humoral and cellular immune responses following immunization. In B6-hHLA-A02:01 mice bearing MC38-hHLA-A02:01-hTAA tumors, mRNA vaccination significantly inhibited tumor growth, validating the model for in vivo efficacy testing. In NCG-M-hHLA-A2.1 mice humanized with HLA-matched hematopoietic stem cells (HSCs), functional reconstitution of human dendritic cells and T cells enabled HLA-A2.1-restricted responses. Therapeutic studies in a patient-derived xenograft (PDX) model demonstrated that mRNA vaccine TA-1 and anti-PD-1 monotherapy each inhibited tumor growth, while the combination achieved superior tumor growth inhibitor.Conclusions This integrated platform, linking human-relevant in vitro immunogenicity assays with a versatile panel of HLA-humanized mouse models (immunocompetent and HSC-reconstituted), provides a robust and translationally relevant system for mRNA cancer vaccine development — from antigen screening to efficacy, combination strategies, and safety profiling. The platform bridges critical gaps in preclinical modeling and supports accelerated clinical translation of next-generation mRNA vaccines.
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $2,490
OpenAlex ID: W7225152909
